Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Engineered T-cell therapy shows efficacy in blood cancer.

Literature DB >> 21997612

Engineered T-cell therapy shows efficacy in blood cancer.

Simon Frantz.

Abstract

Entities: Disease

Mesh：

Substances：
Receptors, Immunologic

Year: 2011 PMID： 21997612 DOI： 10.1038/nbt1011-853

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

6 in total

1. Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells.

Authors: T Brocker
Journal: Blood Date: 2000-09-01 Impact factor: 22.113

2. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

Authors: David L Porter; Bruce L Levine; Michael Kalos; Adam Bagg; Carl H June
Journal: N Engl J Med Date: 2011-08-10 Impact factor: 91.245

3. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.

Authors: Michael Kalos; Bruce L Levine; David L Porter; Sharyn Katz; Stephan A Grupp; Adam Bagg; Carl H June
Journal: Sci Transl Med Date: 2011-08-10 Impact factor: 17.956

4. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors: John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal: Nat Biotechnol Date: 2002-01 Impact factor: 54.908

5. CARs on track in the clinic.

Authors: Donald B Kohn; Gianpietro Dotti; Renier Brentjens; Barbara Savoldo; Michael Jensen; Laurence Jn Cooper; Carl H June; Steven Rosenberg; Michel Sadelain; Helen E Heslop
Journal: Mol Ther Date: 2011-03 Impact factor: 11.454

6. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

Authors: Renier Brentjens; Raymond Yeh; Yvette Bernal; Isabelle Riviere; Michel Sadelain
Journal: Mol Ther Date: 2010-04 Impact factor: 11.454

6 in total

1. Amgen swallows Micromet to BiTE into ALL market.

Authors: Cormac Sheridan
Journal: Nat Biotechnol Date: 2012-04-10 Impact factor: 54.908

2. T-cell immunotherapy: looking forward.

Authors: Jacqueline Corrigan-Curay; Hans-Peter Kiem; David Baltimore; Marina O'Reilly; Renier J Brentjens; Laurence Cooper; Stephen Forman; Stephen Gottschalk; Philip Greenberg; Richard Junghans; Helen Heslop; Michael Jensen; Crystal Mackall; Carl June; Oliver Press; Daniel Powell; Antoni Ribas; Steven Rosenberg; Michel Sadelain; Brian Till; Amy P Patterson; Robert C Jambou; Eugene Rosenthal; Linda Gargiulo; Maureen Montgomery; Donald B Kohn
Journal: Mol Ther Date: 2014-09 Impact factor: 11.454

Review 3. Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.

Authors: Marina O'Reilly; Howard J Federoff; Yuman Fong; Donald B Kohn; Amy P Patterson; Nabil Ahmed; Aravind Asokan; Shannon E Boye; Ronald G Crystal; Satiro De Oliveira; Linda Gargiulo; Scott Q Harper; Yasuhiro Ikeda; Robert Jambou; Maureen Montgomery; Lawrence Prograis; Eugene Rosenthal; Daniel H Sterman; Luk H Vandenberghe; Laurie Zoloth; Mehrdad Abedi; Jennifer Adair; Prasad S Adusumilli; William F Goins; Jhanelle Gray; Paul Monahan; Leslie Popplewell; Miguel Sena-Esteves; Bakhos Tannous; Thomas Weber; William Wierda; Rashmi Gopal-Srivastava; Cheryl L McDonald; Daniel Rosenblum; Jacqueline Corrigan-Curay
Journal: Hum Gene Ther Date: 2014-06 Impact factor: 5.695